Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dirk Thye Insider Profile
11 Followers
Dirk Thye, CMO at Cidara Therapeutics, holds 689.44K shares in Quince Therapeutics (Ticker: QNCX), holds 101.44K shares in Cidara Therapeutics (Ticker: CDTX). Most recently, Dirk Thye Bought ― shares of Quince Therapeutics on Jan 17, 2024 for an estimated value of 190.79K.
Profitable Transactions
0 out of 3 Profitable Transactions
Average Return
-25.20%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Dirk Thye holds in companies
Most Profitable Insider Trade
The most profitable trade made by Dirk Thye
Dirk Thye's Trading History
Cidara Therapeutics
Apr 14, 2015
CMO
Uninformative Buy
―
$1.33M
Quince Therapeutics
Jan 17, 2024
CEO AND CHIEF MEDICAL OFFICER, Director
Informative Buy
190.79K
$627.39K
List of latest transactions for each holding click on a transaction to see Dirk Thye's performance on stock
You May Also Like
Dirk Thye insider profile FAQ
What is the percentage of profitable transactions made by Dirk Thye?
The percentage of profitable transactions made by Dirk Thye is 0%.
What is the average return per transaction made by Dirk Thye?
The average return per transaction made by Dirk Thye is -25.20%.
What stocks does Dirk Thye hold?
Dirk Thye holds: CDTX, QNCX stocks.
What was Dirk Thye’s latest transaction?
Dirk Thye latest transaction was an Informative Buy of $190.79K.
What was Dirk Thye's most profitable transaction?
Dirk Thye’s most profitable transaction was an Informative Buy of QNCX stock on August 9, 2023. The return on the trade was -21.40%.
What is Dirk Thye's role in Cidara Therapeutics?
Dirk Thye's role in Cidara Therapeutics is CMO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.